UNLABELLED: BACKGROUND : Imbalance of glutamatergic neurotransmission has been proposed as a key mechanism underlying symptoms of schizophrenia. The neuropetide N-acetylaspartylglutamate (NAAG) modulates glutamate release. NAAG provides a component of the proton magnetic resonance spectrum (1H-MRS) in humans. The signal of NAAG, however, largely overlaps with its precursor and degrading product N-acetylaspartate (NAA) that by itself does not act in glutamatergic neurotransmission. METHODS: We quantified NAAG and NAA separately from the 1H-MRS signal in 20 patients with schizophrenia and 20 healthy comparison subjects on a 3.0 Tesla MR scanner. The 1H-MRS voxels were positioned in the anterior cingulate cortex (ACC) and in the left frontal lobe. Psychopathological symptoms and cognitive performance were assessed. RESULTS: In the ACC, the ratio NAAG/NAA was increased (P = .041) and NAAG was increased at a trend level (P = .066) in patients, while NAA was reduced (P = .030). NAA correlated with attention performance in patients (r = .64, P = .005) in the ACC. There was no group difference of NAAG, NAA, or NAAG/NAA in the frontal lobe but an inverse correlation of NAAG with negatives symptoms (Positive and Negative Symptoms Scale [PANSS] negative, r = -.58, P = .018) and with the total symptom score (PANSS total, r = -.50, P = .049). In addition, there was a positive correlation of frontal lobe NAAG (r = .53, P = .035) and NAAG/NAA (r = .54, P = .030) with episodic memory in patients. CONCLUSIONS: In this study, we present the first in vivo evidence for altered NAAG concentration in patients with schizophrenia.
UNLABELLED: BACKGROUND : Imbalance of glutamatergic neurotransmission has been proposed as a key mechanism underlying symptoms of schizophrenia. The neuropetide N-acetylaspartylglutamate (NAAG) modulates glutamate release. NAAG provides a component of the proton magnetic resonance spectrum (1H-MRS) in humans. The signal of NAAG, however, largely overlaps with its precursor and degrading product N-acetylaspartate (NAA) that by itself does not act in glutamatergic neurotransmission. METHODS: We quantified NAAG and NAA separately from the 1H-MRS signal in 20 patients with schizophrenia and 20 healthy comparison subjects on a 3.0 Tesla MR scanner. The 1H-MRS voxels were positioned in the anterior cingulate cortex (ACC) and in the left frontal lobe. Psychopathological symptoms and cognitive performance were assessed. RESULTS: In the ACC, the ratio NAAG/NAA was increased (P = .041) and NAAG was increased at a trend level (P = .066) in patients, while NAA was reduced (P = .030). NAA correlated with attention performance in patients (r = .64, P = .005) in the ACC. There was no group difference of NAAG, NAA, or NAAG/NAA in the frontal lobe but an inverse correlation of NAAG with negatives symptoms (Positive and Negative Symptoms Scale [PANSS] negative, r = -.58, P = .018) and with the total symptom score (PANSS total, r = -.50, P = .049). In addition, there was a positive correlation of frontal lobe NAAG (r = .53, P = .035) and NAAG/NAA (r = .54, P = .030) with episodic memory in patients. CONCLUSIONS: In this study, we present the first in vivo evidence for altered NAAG concentration in patients with schizophrenia.
Authors: Jazmin Camchong; Kara A Dyckman; Benjamin P Austin; Brett A Clementz; Jennifer E McDowell Journal: Biol Psychiatry Date: 2008-08-09 Impact factor: 13.382
Authors: Sandeep T Patil; Lu Zhang; Ferenc Martenyi; Stephen L Lowe; Kimberley A Jackson; Boris V Andreev; Alla S Avedisova; Leonid M Bardenstein; Issak Y Gurovich; Margarita A Morozova; Sergey N Mosolov; Nikolai G Neznanov; Alexander M Reznik; Anatoly B Smulevich; Vladimir A Tochilov; Bryan G Johnson; James A Monn; Darryle D Schoepp Journal: Nat Med Date: 2007-09-02 Impact factor: 53.440
Authors: Jean Théberge; Yousef Al-Semaan; Peter C Williamson; Ravi S Menon; Richard W J Neufeld; Nagalingam Rajakumar; Betsy Schaefer; Maria Densmore; Dick J Drost Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112
Authors: Tomás R Guilarte; Dima A Hammoud; Jennifer L McGlothan; Brian S Caffo; Catherine A Foss; Alan P Kozikowski; Martin G Pomper Journal: Schizophr Res Date: 2008-01-10 Impact factor: 4.939
Authors: Rosalinda C Roberts; Lesley A McCollum; Kirsten E Schoonover; Samuel J Mabry; Joy K Roche; Adrienne C Lahti Journal: Schizophr Res Date: 2020-01-31 Impact factor: 4.939
Authors: Simon E Ward; Paul Beswick; Novella Calcinaghi; Lee A Dawson; Jane Gartlon; Francesca Graziani; Declan N C Jones; Laurent Lacroix; M H Selina Mok; Beatrice Oliosi; Joanne Pardoe; Kathryn Starr; Marie L Woolley; Mark H Harries Journal: Br J Pharmacol Date: 2017-01-31 Impact factor: 8.739
Authors: Joseph L McClay; Sarah A Vunck; Angela M Batman; James J Crowley; Robert E Vann; Patrick M Beardsley; Edwin J van den Oord Journal: J Neuroimmune Pharmacol Date: 2015-04-08 Impact factor: 4.147
Authors: Kristen A Rahn; Crystal C Watkins; Jesse Alt; Rana Rais; Marigo Stathis; Inna Grishkan; Ciprian M Crainiceau; Martin G Pomper; Camilo Rojas; Mikhail V Pletnikov; Peter A Calabresi; Jason Brandt; Peter B Barker; Barbara S Slusher; Adam I Kaplin Journal: Proc Natl Acad Sci U S A Date: 2012-11-19 Impact factor: 11.205
Authors: Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone Journal: Neuropsychopharmacology Date: 2012-07-04 Impact factor: 7.853
Authors: Laura M Rowland; Kimberly Kontson; Jeffrey West; Richard A Edden; He Zhu; S Andrea Wijtenburg; Henry H Holcomb; Peter B Barker Journal: Schizophr Bull Date: 2012-10-18 Impact factor: 9.306